Havas Life NY finds a new leader in WebMD's Gemmell

Share this article:
Dorothy Gemmell
Dorothy Gemmell

Havas has hired a longtime WebMD exec to lead Havas Life New York.

Dorothy Gemmell, who was SVP, sales and sales operations at WebMD, becomes president of the agency, which was formerly known as Euro RSCG Life MetaMax.

Gemmell spent 13 years at WebMD, where she sat on the executive leadership committee. In her most recent role there, she led WebMD's global biopharmaceutical and medical device businesses, along with WebMD The Magazine and its sales, revenue and advertising operations groups.

Gemmell got her start in healthcare marketing at Upjohn in 1989. She calls herself a career “serial monogamist” – by the time she left ten years later, the company, now part of Pfizer, was called Pharmacia and she was working in global marketing. She joined MedScape, a client from her Pharmacia days.

She takes over at Havas' most global shop. More than two-thirds of Havas Life New York's business involves ex-US work. “They've been really successful at diversifiying the brands they work with,” she said, “and there's a huge opportunity to continue that growth path.”

Her availability, said global CEOs Doug Burcin and Donna Murphy in a statement, “presented us an opportunity to bring in a fresh leadership perspective.”

Gemmell replaces a team of co-managing directors, Laurel Rossi and Marc Porter, at the shop. Rossi is back to running the agency she founded and sold to Havas, Strat Farm, full time, while Porter has left the company.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?